Lilly Alimta For Lung Cancer “Reasonably Likely” To Improve Survival
Executive Summary
Lilly's Alimta is "reasonably likely" to improve survival in non-small cell lung cancer patients despite not meeting the primary endpoint of overall survival in pivotal trials, labeling says
You may also be interested in...
PDUFA IV Fix For FDA Performance On Standard Reviews Advocated By BIO
Prescription Drug User Fee Act negotiations should address the discrepancy in FDA performance on approval times for standard and priority review applications, Biotechnology Industry Organization's Amit Sachdev said
PDUFA IV Fix For FDA Performance On Standard Reviews Advocated By BIO
Prescription Drug User Fee Act negotiations should address the discrepancy in FDA performance on approval times for standard and priority review applications, Biotechnology Industry Organization's Amit Sachdev said
Taxotere Sales Force Restructured To Bolster Growth, Fend Off Competition
Sanofi-Aventis has reorganized its U.S. Taxotere sales force to drive growth of the oncologic amid an increasingly competitive environment, the firm said